Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dual Tobacco Use Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes

NCT06614504
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Varying the nicotine content of cigarettes, Varying the nicotine content of e-cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
21 Years and older
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Providence, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Post-Market Surveillance of Tobacco Products

NCT04255459
View directory record Official record
Conditions
Smoking, Tobacco, Smoking Behaviors
Interventions
Moist Snuff, Camel Snus, Cigarettes, No tobacco usage
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
19 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
6
States / cities
DeLand, Florida • Miramar, Florida • Stockbridge, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers

NCT07215923
View directory record Official record
Conditions
Thromboangiitis Obliterans (Buerger's Disease)
Interventions
ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo
Biological · Other
Lead sponsor
Antidote Therapeutics, Inc
Industry
Eligibility
23 Years to 59 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

NCT02355665
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Nicotine Spray, Placebo
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Burbank, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes

NCT02385227
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Exclusive blu™ e-cigarette A1, Exclusive blu™ e-cigarette A2, Exclusive blu™ e-cigarette A3, Dual blu™ e-cigarette and usual brand B1, Dual blu™ e-cigarette and usual brand B2, Dual blu™ e-cigarette and usual brand B3, Nicotine product cessation C
Other
Lead sponsor
Lorillard Tobacco Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Addictive Potential of LCCs in Dual Users

NCT03496077
View directory record Official record
Conditions
Tobacco Use Disorder, Dual Tobacco Use, Tobacco Dependence, Smoking, Smoking, Cigar, Smoking, Cigarette, Smoking, Tobacco
Interventions
Flavored and unflavored little cigars/cigarillos (LCCs)
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 34 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking

NCT00218465
View directory record Official record
Conditions
Nicotine Dependence
Interventions
GW468816, Placebo Comparator: Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 3 Interventional

NicVAX/Placebo as an Aid for Smoking Cessation

NCT00836199
View directory record Official record
Conditions
Smoking Cessation, Smoking, Tobacco Cessation
Interventions
NicVAX vaccine, Placebo vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

NCT02796651
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease - COPD
Interventions
Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dyadic Financial Incentive Treatments for Dual Smoker Couples

NCT06296849
View directory record Official record
Conditions
Smoking, Cigarette
Interventions
Financial Incentive Treatment (FIT)
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Athens, Georgia • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes

NCT02416011
View directory record Official record
Conditions
Smoking Cessation
Interventions
GENERIC, eTARGET
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2,896 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Not applicable Interventional

Cessation of Dual Use of Cigarettes and E-cigarettes During Pregnancy

NCT07124702
View directory record Official record
Conditions
Dual Use of Cigarettes and E-cigarettes, Gestational Weight Gain, Birth-weight-for-gestational-age z Score
Interventions
Simultaneous cessation intervention, Stepwise cessation intervention, Behavior counseling only
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 28, 2026, 2:39 AM EDT
Terminated Phase 3 Interventional Results available

Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking

NCT01296698
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Placebo, Nicotine
Drug
Lead sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Muscle Shoals, Alabama • Oceanside, California • Griffin, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 28, 2026, 2:39 AM EDT
Recruiting Not applicable Interventional

Pilot Study of Communication for Dual Users of Cigarettes and E-cigarettes

NCT07599462
View directory record Official record
Conditions
Tobacco Products, Cigarettes, Electronic Cigarettes
Interventions
communication
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Not yet recruiting Phase 2 Interventional

DOSE-UP: Dose Optimization for Smoking and E-Cigarette Use Pharmacotherapy

NCT07754578
View directory record Official record
Conditions
Dual Use of Cigarettes and E-cigarettes
Interventions
Text- and web-based support, Nicotine Replacement Therapy (NRT, nicotine patch), Nicotine replacement therapy lozenge
Behavioral · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia

NCT01213524
View directory record Official record
Conditions
Tobacco Use Disorder, Schizophrenia
Interventions
sensorimotor replacement, 42 mg transdermal nicotine replacement, Placebo transdermal nicotine, usual brand smoking
Behavioral · Drug · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years to 99 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Selegiline for Smoking Cessation - 1

NCT00439413
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Selegiline Transdermal Patch, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
College Park, Maryland • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 28, 2026, 2:39 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

E-Cigarette and Cigarette Nicotine Delivery and Abuse Liability in Cigarette Smokers and Dual Users

NCT03943706
View directory record Official record
Conditions
Tobacco Use
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen in Reducing Cigarette Craving in Smokers

NCT01337830
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Ariva® Silver Wintergreen, Silver Wintergreen
Other
Lead sponsor
Star Scientific, Inc
Industry
Eligibility
23 Years to 72 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Martinsburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 3 Interventional

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

NCT01102114
View directory record Official record
Conditions
Smoking Cessation
Interventions
NicVAX Vaccine, Placebo Vaccine
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Encino, California • Los Alamitos, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers

NCT01262170
View directory record Official record
Conditions
Smoking, Tobacco Use Disorder
Interventions
CigRx Lozenge, Tobacco Lozenge
Dietary Supplement · Other
Lead sponsor
Rock Creek Pharmaceuticals, Inc.
Industry
Eligibility
23 Years to 72 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Martinsburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

NCT01188967
View directory record Official record
Conditions
Nicotine Dependence
Interventions
GSK598809, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 28, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319
View directory record Official record
Conditions
Depressive Disorder
Interventions
Mecamylamine hydrochloride (Inversine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 28, 2026, 2:39 AM EDT